Preparation of intravenous drug administration guidelines for a pediatric intensive care unit.

J Infus Nurs

Pharmacy Department, Gregorio Marañón Hospital, Madrid, Spain (Drs Manrique-Rodríguez, Fernández-Llamazares, Echarri-Martínez, and Sanjurjo-Sáez); Paediatric Intensive Care Department, Gregorio Marañón Hospital, Madrid, Spain (Ms Rodríguez-Gómez); and Paediatric Intensive Care Department, Gregorio Marañón Hospital, Madrid, Spain (Drs Sánchez-Galindo, López-Herce, and Carrillo-Álvarez). Silvia Manrique-Rodríguez, PharmD, PhD, is a Clinical Hospital Pharmacist, Gregorio Marañón Hospital, Madrid, Spain. Amelia Sánchez-Galindo, MD, is an Intensive Care Pediatrician, Gregorio Marañón Hospital, Madrid, Spain. Cecilia M. Fernández-Llamazares, PharmD, PhD, is a Clinical Hospital Pharmacist, Gregorio Marañón Hospital, Madrid, Spain. Jesús López-Herce, MD, PhD, is an Intensive Care Pediatrician, Gregorio Marañón Hospital, Madrid, Spain. Milagrosa Rodríguez-Gómez is Chief Nurse, Pediatric lntensive Care Unit, Gregorio Marañón Hospital, Madrid, Spain. Lara Echarri-Martínez, PharmD, is a Clinical Hospital Pharmacist, Gregorio Marañón Hospital, Madrid, Spain. Ángel Carrillo-Álvarez, MD, PhD, is Director of Pediatric Intensive Care Unit, Gregorio Marañón Hospital, Madrid, Spain. María Sanjurjo-Sáez, PharmD, is Director of Pharmacy Department, Gregorio Marañón Hospital, Madrid, Spain.

Published: April 2015

Drug administration is one of the main sources of errors in pediatric intensive care units (PICUs). An available guide for intravenous drug administration might be useful. The aim of this article is to present the methodology and results for the development of a guide for intravenous drug administration in a PICU. A total of 116 drugs were included. Standard concentrations, diluents, technique for reconstitution and dilution, stability, rate of administration, and relevant observations were defined for each drug according to a review of the most commonly used literature resources. The main unique feature of this article is that it includes standard concentrations for each drug.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NAN.0000000000000019DOI Listing

Publication Analysis

Top Keywords

drug administration
16
intravenous drug
12
pediatric intensive
8
intensive care
8
guide intravenous
8
standard concentrations
8
drug
6
administration
5
preparation intravenous
4
administration guidelines
4

Similar Publications

Background: Historically, soil-transmitted helminth (STH) control and prevention strategies have relied on mass drug administration efforts targeting preschool and school-aged children. While these efforts have succeeded in reducing morbidity associated with STH infection, recent modeling efforts have suggested that expanding intervention to treatment of the entire community could achieve transmission interruption in some settings. Testing the feasibility of such an approach requires large-scale clinical trials, such as the DeWorm3 cluster randomized trial.

View Article and Find Full Text PDF

Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).

Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring.

Results: During the study period (June 15, 2011-June 14, 2016), 94.

View Article and Find Full Text PDF

Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-eight participants with risk factors of metabolic syndrome according to the inclusion criteria were randomized into two groups and given probiotics (Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1) (n = 31) or a placebo (n = 27).

View Article and Find Full Text PDF

Background: As an opportunistic bacterial pathogen, Klebsiella pneumoniae (KP) is prone to causing a spectrum of diseases in rabbits when their immune system is compromised, which poses a threat to rabbit breeding industry. Bacillus coagulans (BC), recognized as an effective probiotic, confers a variety of benefits including anti-inflammatory and antioxidant properties.

Aim: The purpose of this study was to investigate whether dietary BC can effectively alleviate hepatic injury caused by KP.

View Article and Find Full Text PDF

Introduction: Effective antimicrobial stewardship programs require data on antimicrobial consumption (AMC) and utilization (AMU) to guide interventions. However, such data is often scarce in low-resource settings. We describe the consumption and utilization of antibiotics at a large tertiary-level hospital in Uganda.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!